Gultekin Murat, Dundar Selin, Kucukyildiz Irem, Karaca Mujdegul Zayifoglu, Boztas Guledal, Turan Semra Hatice, Hacikamiloglu Ezgi, Keskinkilic Bekir
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Department of Cancer Control, Public Health Institute, Turkish Ministry of Health, Ankara, Turkey.
J Gynecol Oncol. 2017 Nov;28(6):e85. doi: 10.3802/jgo.2017.28.e85.
To investigate the 5-year relative survival rates in gynecological cancers diagnosed and treated in Turkey by year 2009 and to compare the results with developed countries.
Data of patients diagnosed for ovarian, corpus uteri or cervix uteri cancer at year 2009 are collected from 9 national cancer registry centers. Date of deaths are retracted from governmental Identity Information Sharing System (KPS). In order to calculate relative survival rates, national general population mortality tables are obtained from Turkish Statistical Institute (TurkStat). Hakulinen method is used for computing curves by R program. Data for European, Asian and some developed countries were obtained from official web pages.
A total of 1,553 patients are evaluated. Among these, 713 (45.9%) are corpus uteri cancers, while remaining 489 (31.5%) are ovarian and 351 (22.6%) are cervix uteri. Five-year overall relative survival rates are 85%, 50%, and 62% for corpus uteri, ovarian, and cervix uteri, respectively. These figures are between 73%-87% for corpus uteri, 31%-62% for ovarian and 61%-80% for cervix uteri in developed countries. Stage is the most important factor for survival in all cancers. Five-year relative survival rates in corpus uteri cancers are 92%, 66%, and 38% for localized, regional, and distant metastatic disease, respectively. These figures are 77%, 57%, and 29% for ovarian; 80%, 50%, and 22% for cervix uteri.
This is the first report from Turkey giving national overall relative survival for gynecological cancers from a population based cancer registry system.
调查截至2009年在土耳其诊断和治疗的妇科癌症患者的5年相对生存率，并将结果与发达国家进行比较。
从9个国家癌症登记中心收集2009年诊断为卵巢癌、子宫体癌或子宫颈癌的患者数据。死亡日期从政府身份信息共享系统（KPS）中获取。为了计算相对生存率，从土耳其统计研究所（TurkStat）获取全国普通人群死亡率表。使用R程序通过哈库利宁方法计算曲线。欧洲、亚洲和一些发达国家的数据从官方网页获取。
共评估了1553例患者。其中，713例（45.9%）为子宫体癌，其余489例（31.5%）为卵巢癌，351例（22.6%）为子宫颈癌。子宫体癌、卵巢癌和子宫颈癌的5年总体相对生存率分别为85%、50%和62%。在发达国家，这些数字子宫体癌在73%-87%之间，卵巢癌在31%-62%之间，子宫颈癌在61%-80%之间。分期是所有癌症生存的最重要因素。子宫体癌局限期、区域期和远处转移期疾病的5年相对生存率分别为92%、66%和38%。卵巢癌的这些数字分别为77%、57%和29%；子宫颈癌分别为80%、50%和22%。
这是土耳其第一份基于人群癌症登记系统给出妇科癌症全国总体相对生存率的报告。
